|
|||||
|
|
A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer |
|
| Authors: | Michael J. Pishvaian MD PhD Rebecca S. Slack MS Wei Jiang MS A. Ruth He MD PhD Jimmy J. Hwang MD Amy Hankin NP Karen Dorsch‐Vogel RN Divyesh Kukadiya MS Louis M. Weiner MD John L. Marshall MD Jonathan R. Brody PhD |
| Affiliation: | 1. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC;2. The University of Texas MD Anderson Cancer Center, Houston, Texas;3. Carolinas Medical Center, Charlotte, North Carolina;4. Jefferson Pancreas, Biliary, and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania;5. Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania;6. Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania |
| Abstract: | |
| Keywords: | colorectal cancer mismatch repair genes O(6)‐methylguanine‐DNA methyltransferase (MGMT) phosphatase and tensin homolog deleted on chromosome 10 (PTEN) temozolomide veliparib |